Breaking News, Financial News

Financial Report: Hospira 3Q09

In the quarter, Global Specialty Injectables revenue was $575.7 million (+24%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira 3Q09 3Q Revenues: $1.0 billion (+9%) 3Q Earnings: $116.2 million (+42%) YTD Revenues: $2.8 billion (+4%) YTD Earnings: $307.2 million (+42%) Comments: In the quarter, Global Specialty Injectables revenue was $575.7 million (+24%). In the Americas, sales were $449.1 million (+32%). Asia Pacific sales were flat at $57.0 million. Revenue for Other Pharma (including contract manufacturing) was down 2% to $126.0 million in 3Q09. Global Specialty Injectables revenue YTD was $1.5...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters